DM204 / DiaMedica - LARVOL DELTA

DUALIDES: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=23; Completed; Sponsor: Orion Corporation, Orion Pharma; N=75 ➔ 23

Clinical • Enrollment change • KLK3

DUALIDES: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=75; Active, not recruiting; Sponsor: Orion Corporation, Orion Pharma; Recruiting ➔ Active, not recruiting; Trial primary completion date: May 2017 ➔ Dec 2017

Clinical • Enrollment closed • Trial primary completion date

DUALIDES: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=75; Recruiting; Sponsor: Orion Corporation, Orion Pharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

DUALIDES: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=75; Not yet recruiting; Sponsor: Orion Corporation, Orion Pharma

Clinical • New P1/2 trial

DUALIDES: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=75; Completed; Sponsor: Orion Corporation, Orion Pharma; Active, not recruiting ➔ Completed

Clinical • Trial completion

DUALIDES: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=75; Active, not recruiting; Sponsor: Orion Corporation, Orion Pharma; Trial completion date: Dec 2017 ➔ Dec 2018; Trial primary completion date: Dec 2017 ➔ Dec 2018

Clinical • Trial completion date • Trial primary completion date